| Name | BAZ1A-IN-1 |
| Description | BAZ1A-IN-1 is a potent BAZ1A inhibitor with a KD value of 0.52 μM for the BAZ1A bromodomain, demonstrating strong anti-survival activity against cancer cell lines with high BAZ1A expression and weak or no activity against cancer cells with low BAZ1A expression. |
| In vitro | Administration of BAZ1A-IN-1 (0.015-100?μM; 96 hours) exhibits good anti-viability activity against all the four cancer cell lines that have a high expression level of BAZ1A, with IC50 values of 5.08 μM, 4.29 μM, 10.65 μM, and 7.70 μM for THP-1, ZR-75-30, BT474, and H1975 cells, respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (235.05 mM)
|
| Keywords | leukemia | breast cancer | Epigenetic Reader Domain | BAZ1A IN 1 | cancer | ZR-75–30 | BAZ1A | BAZ1AIN1 | THP-10 | bromodomain-containing | lung cancer | H1975 | inhibit | BAZ-1A-IN-1 | BT474 | BAZ1A-IN-1 | Inhibitor |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin | GSK1379725A |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
